MA50041A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents

Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Info

Publication number
MA50041A
MA50041A MA050041A MA50041A MA50041A MA 50041 A MA50041 A MA 50041A MA 050041 A MA050041 A MA 050041A MA 50041 A MA50041 A MA 50041A MA 50041 A MA50041 A MA 50041A
Authority
MA
Morocco
Prior art keywords
preparation
methods
same
spirocyclic compounds
spirocyclic
Prior art date
Application number
MA050041A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Todd K Jones
Michael B Shaghafi
Olivia D Weber
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of MA50041A publication Critical patent/MA50041A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA050041A 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci MA50041A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
MA50041A true MA50041A (fr) 2020-07-08

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050041A MA50041A (fr) 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Country Status (27)

Country Link
US (1) US11142526B2 (fr)
EP (1) EP3675847B1 (fr)
JP (1) JP7257387B2 (fr)
KR (1) KR20200046061A (fr)
CN (1) CN111050765B (fr)
AU (1) AU2018323459A1 (fr)
BR (1) BR112020004101A2 (fr)
CA (1) CA3072923A1 (fr)
CL (1) CL2020000462A1 (fr)
CO (1) CO2020001724A2 (fr)
CR (1) CR20200089A (fr)
DO (1) DOP2020000039A (fr)
EA (1) EA202090312A1 (fr)
EC (1) ECSP20013337A (fr)
ES (1) ES2952332T3 (fr)
GE (2) GEP20217327B (fr)
IL (1) IL272580B (fr)
JO (1) JOP20200023A1 (fr)
MA (1) MA50041A (fr)
MX (1) MX2020002251A (fr)
NI (1) NI202000014A (fr)
PE (1) PE20200664A1 (fr)
PH (1) PH12020500372A1 (fr)
SG (1) SG11202001022TA (fr)
UA (1) UA126685C2 (fr)
WO (1) WO2019046318A1 (fr)
ZA (1) ZA202001208B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
WO2017197192A1 (fr) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
CN114096545A (zh) * 2019-07-09 2022-02-25 豪夫迈·罗氏有限公司 新杂环化合物
JP7785755B2 (ja) * 2020-08-26 2025-12-15 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤として有用な複素環化合物
TWI904281B (zh) * 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
CA3242372A1 (fr) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibition de la monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (fr) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368354A1 (fr) * 2001-03-07 2003-12-10 Pfizer Products Inc. Modulateurs de l'activite du recepteur de la chimiokine
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
ME03452B (fr) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disubstitué octahy - dropyrrolo [3,4-c] pyrroles en tant que modulateurs du récepteur de l'orexine
CA2791672A1 (fr) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Modulateurs allosteriques positifs de mglur2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
CA2917050A1 (fr) 2013-07-03 2015-01-08 Todd K. Jones Composes de pyrrolo-pyrrole carbamate et composes organiques associes, compositions pharmaceutiques et leurs utilisations medicales
WO2015179559A2 (fr) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
ES2878041T3 (es) * 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2017087858A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
WO2017197192A1 (fr) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
DK3541807T3 (da) 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
KR20190085046A (ko) 2016-11-16 2019-07-17 어바이드 테라퓨틱스, 인크. 약학 제제
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法

Also Published As

Publication number Publication date
US20200255427A1 (en) 2020-08-13
CN111050765B (zh) 2024-01-02
RU2020107163A (ru) 2021-09-30
WO2019046318A1 (fr) 2019-03-07
JOP20200023A1 (ar) 2020-02-02
EP3675847B1 (fr) 2023-07-12
ECSP20013337A (es) 2020-04-22
IL272580B (en) 2022-09-01
EA202090312A1 (ru) 2020-08-05
ES2952332T3 (es) 2023-10-30
PE20200664A1 (es) 2020-06-11
CN111050765A (zh) 2020-04-21
EP3675847C0 (fr) 2023-07-12
CR20200089A (es) 2020-04-08
RU2020107163A3 (fr) 2022-03-15
JP7257387B2 (ja) 2023-04-13
IL272580A (en) 2020-03-31
CO2020001724A2 (es) 2020-02-28
CA3072923A1 (fr) 2019-03-07
CL2020000462A1 (es) 2020-07-10
GEAP202115281A (en) 2021-08-10
EP3675847A1 (fr) 2020-07-08
UA126685C2 (uk) 2023-01-11
US11142526B2 (en) 2021-10-12
SG11202001022TA (en) 2020-03-30
KR20200046061A (ko) 2020-05-06
PH12020500372A1 (en) 2020-12-07
EP3675847A4 (fr) 2021-01-06
GEP20217327B (en) 2021-12-10
JP2020532545A (ja) 2020-11-12
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
DOP2020000039A (es) 2020-08-31
AU2018323459A1 (en) 2020-02-20
BR112020004101A2 (pt) 2020-09-24
ZA202001208B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
EP3675848A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3370715A4 (fr) Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
EP3455226A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3463665A4 (fr) Surfaces modifiées par covalence, kits et procédés de préparation et d'utilisation
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA54252A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3271352A4 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
EP3359164A4 (fr) Composés et procédés pour moduler l'expression de l'angiotensinogène
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3526205A4 (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3429754A4 (fr) Cartouches de préparation d'échantillons et leurs procédés d'utilisation
EP3662007A4 (fr) Agents de matité à base de silice et procédés de préparation et d'utilisation desdits agents
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation